P&G Pharma Sale Could Bring $1 Billion To Feed Consumer Business
This article was originally published in The Tan Sheet
Executive Summary
A sale of Procter & Gamble's pharma business could fetch about $1 billion, according to an estimate by one analyst. That represents cash P&G could reinvest in its core business areas, beauty and consumer health care, at a time when the recession is impacting growth and the credit crisis is forcing some retailers to cut inventories to conserve cash
You may also be interested in...
P&G Kisses Pharma Biz Goodbye In $3.1B Deal With Warner Chilcott
Warner Chilcott's $3.1 billion acquisition of Proctor & Gamble's pharmaceuticals business on Aug. 24 significantly bolsters the Irish drug maker's sales force and adds to its already lucrative women's health portfolio with the addition of Asacol HD and Actonel,while freeing P&G to focus on consumer health
P&G Kisses Pharma Business Goodbye In $3.1 Billion Deal With Warner Chilcott
Ireland-based Warner Chilcott has a "double tax haven," making the P&G deal one with fairly low financial risks, Wall Street analysts say.
Switch Projected To Continue Driving OTC Market Growth In 5-Year Picture
Market researchers see multiple factors affecting the outlook for Rx-to-OTC switches, which remain the biggest growth driver in the nonprescription arena